Etanercept with IVIg for acute Kawasaki disease: a long-term follow-up on the EATAK trial

• Published in: Cardiology in the young Vol. 33; no. 4; p. 613
• Main Authors: Sagiv, Eyal, Slee, April, Buffone, Ashley, Choueiter, Nadine F, Dahdah, Nagib S, Portman, Michael A
• Format: Journal Article
• Language: English
• Published: England 01-04-2023
• Subjects: Acute Disease; Child; Coronary Aneurysm - drug therapy; Coronary Artery Disease - drug therapy; Etanercept - therapeutic use; Follow-Up Studies; Humans; Immunoglobulins, Intravenous - therapeutic use; Infant; Mucocutaneous Lymph Node Syndrome - complications; Mucocutaneous Lymph Node Syndrome - drug therapy; tumour necrosis factor; coronary arteries; Etanercept; vasculitis; Kawasaki
• ISSN: 1467-1107
• DOI: 10.1017/S1047951122001470

The Etanercept as Adjunctive Treatment for Acute Kawasaki Disease, a phase-3 clinical trial, showed that etanercept reduced the prevalence of IVIg resistance in acute Kawasaki disease. In patients who presented with coronary artery involvement, it reduced the maximal size and short-term progression of coronary artery dilation. Following up with this patient group, we evaluated the potential long-term benefit of etanercept for coronary disease.
Patients were followed for at least 1 year after the trial. The size of dilated arteries (z-score ≥ 2.5) was measured at each follow-up visit. The z-score and size change from baseline were evaluated at each visit and compared between patients who received etanercept versus placebo at the initial trial.
Forty patients who received etanercept (22) or placebo (18) in the Etanercept as Adjunctive Treatment for Acute Kawasaki Disease trial were included. All patients showed a persistent decrease in coronary artery size measurement: 23.3 versus 5.9% at the 6-month visit, 24 versus 13.1% at the 1-year visit, and 20.8 versus 19.3% at the ≥ 2-year visit for etanercept or placebo, respectively, with similar results for decrease in coronary artery z-scores. In a multivariate analysis, correcting for patients' growth, a greater size reduction for patients on the etanercept arm versus placebo was proved significant for the 6-month (p = 0.005) and the 1-year visits (p = 0.019) with a similar end outcome at the ≥ 2-year visit.
Primary adjunctive therapy with etanercept for children with acute Kawasaki disease does not change the end outcome of coronary artery disease but may promote earlier resolution of artery dilation.